Literature DB >> 12640222

Concomitant use of antipsychotics and drugs that may prolong the QT interval.

Catherine M Roe1, Kevin W Odell, Rochelle R Henderson.   

Abstract

Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1,139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 51% of QT antipsychotic group members used other QT drugs concomitantly for at least 1 day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled ( p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640222     DOI: 10.1097/00004714-200304000-00013

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  12 in total

Review 1.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 2.  Pharmacogenetics in drug regulation: promise, potential and pitfalls.

Authors:  Rashmi R Shah
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 3.  [Differences between men and women in side effects of second-generation antipsychotics].

Authors:  W Aichhorn; A B Whitworth; E M Weiss; H Hinterhuber; J Marksteiner
Journal:  Nervenarzt       Date:  2007-01       Impact factor: 1.214

Review 4.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 5.  Pharmacogenetic issues in thorough QT trials.

Authors:  Richard S Judson; Benjamin A Salisbury; Carol R Reed; Michael J Ackerman
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

6.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  Circulation       Date:  2010-02-08       Impact factor: 29.690

Review 7.  Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Barbara J Drew; Michael J Ackerman; Marjorie Funk; W Brian Gibler; Paul Kligfield; Venu Menon; George J Philippides; Dan M Roden; Wojciech Zareba
Journal:  J Am Coll Cardiol       Date:  2010-03-02       Impact factor: 24.094

Review 8.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  QTc Prolongation and the Use of Antipsychotics: A Case Discussion.

Authors:  Jeff C. Huffman; Theodore A. Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-12

10.  New Generation Antipsychotic Drugs and QTc Interval Prolongation.

Authors:  W VictorR Vieweg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.